Company profile: IDEC Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of therapy development targeting neurodegenerative, hematologic, and autoimmune diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IDEC Pharmaceuticals
Marengo Therapeutics
HQ: United States
Website
- Description: Provider of T cell–modulating antibody platforms and therapeutics, including the STAR bi-functional molecule platform pairing anti-Vβ antibodies with costimulatory signals for antigen-rich 'hot' tumors; the TriSTAR T cell engager for antigen-low 'cold' tumors; TCR-targeting antibodies; an antibody technology platform using genomics and TCR sequencing; and STAR0602, in Phase I/II (START-001) for advanced antigen-rich solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marengo Therapeutics company profile →
Propella Therapeutics
HQ: United States
Website
- Description: Provider of lymphatic-targeted oncology therapeutics and a lymphatic targeting drug delivery platform. Uses medicinal chemistry to adapt known actives with validated mechanisms for lymphatic delivery. Pipeline includes PRL-02 (abiraterone decanoate, intramuscular) for advanced prostate cancer, targeting the androgen receptor pathway by inhibiting CYP17, delivered via the lymphatic system to enhance efficacy and safety by bypassing the liver and reducing plasma exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Propella Therapeutics company profile →
Medical Prognosis Institute
HQ: Denmark
Website
- Description: Provider of drug targeting, pharmaco Dx, and DNA microarray services for research projects in Denmark, supporting drug development, individual cancer prognostication and drug sensitivity prediction, and gene/drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medical Prognosis Institute company profile →
DiaCarta
HQ: United States
Website
- Description: Provider of precision molecular diagnostics, including CE/IVD-marked KRAS detection, for cancer screening, monitoring, and therapy guidance. Offerings include RadTox for real-time cfDNA treatment response; ColoScape for colorectal screening and FIT-positive triage via plasma cfDNA changes; QClamp for sensitive ctDNA mutation detection; OptiSeq Colorectal Cancer NGS Panel for actionable mutations; Oncuria urine biomarkers; and custom mini-MRD panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiaCarta company profile →
Step Pharma
HQ: France
Website
- Description: Provider of CTPS1 inhibition therapies, developing STP938, an orally bioavailable CTPS1 inhibitor in clinical development for treating blood cancers and potentially solid tumors. The approach targets the CTPS1 enzyme to inhibit a key step in nucleotide synthesis to treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Step Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IDEC Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IDEC Pharmaceuticals
2.2 - Growth funds investing in similar companies to IDEC Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IDEC Pharmaceuticals
4.2 - Public trading comparable groups for IDEC Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →